

Resource Summary Report

Generated by [nidm-terms](#) on Aug 25, 2026

DDB1 Antibody

RRID:AB_10634753

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 5428, RRID:AB_10634753

Antibody Information

URL: http://antibodyregistry.org/AB_10634753

Proper Citation: Cell Signaling Technology Cat# 5428, RRID:AB_10634753

Target Antigen: DDB1

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W

Antibody Name: DDB1 Antibody

Description: This polyclonal targets DDB1

Target Organism: Human, Rat, Monkey, Mouse

Antibody ID: AB_10634753

Vendor: Cell Signaling Technology

Catalog Number: 5428

Alternative Catalog Numbers: 5428S

Record Creation Time: 20250819T231934+0000

Record Last Update: 20250820T045943+0000

Ratings and Alerts

No rating or validation information has been found for DDB1 Antibody.

No alerts have been found for DDB1 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Wang K, et al. (2026) CAND1 and CAND2 drive CUL4 substrate receptor exchange with largely comparable biochemical efficiency, unlike their relative effects on CUL1. Structure (London, England : 1993), 34(6), 963.

Mangano K, et al. (2025) VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation. Cell chemical biology, 32(3), 423.

Townsend A, et al. (2021) DCAF14 promotes stalled fork stability to maintain genome integrity. Cell reports, 34(4), 108669.

Minamino M, et al. (2018) Temporal Regulation of ESCO2 Degradation by the MCM Complex, the CUL4-DDB1-VPRBP Complex, and the Anaphase-Promoting Complex. Current biology : CB, 28(16), 2665.

Lu G, et al. (2018) UBE2G1 governs the destruction of cereblon neomorphic substrates. eLife, 7.

Kiran S, et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Molecular cell, 72(5), 823.